Nemus Bioscience, Inc. is a clinical-stage biotechnology company focused on the research, development, and commercialization of phytocannabinoid-derived prescription therapies. Headquartered in Neptune Beach, Florida, Nemus leverages its proprietary Indasci™ delivery platform to formulate cannabinoid-based medicines aimed at ocular, dermatologic and gastrointestinal indications. The company’s pipeline includes NMUS-420, a sustained-release formulation of delta-8-tetrahydrocannabinol (D8-THC) in development for glaucoma, and NMUS-130, a topical cannabinoid candidate targeting inflammatory skin conditions.
Originally incorporated as BioCorRx, the company rebranded to Nemus Bioscience in 2019 to reflect its strategic pivot towards prescription cannabinoid pharmaceuticals. Over the years, Nemus has established research collaborations and licensing arrangements to support its preclinical and clinical programs, with manufacturing partnerships in both North America and Europe. The company maintains in-house capabilities in formulation science, pharmacology, and preclinical testing, enabling it to advance multiple product candidates through IND-enabling studies.
Leadership at Nemus is led by William “Chip” Culbertson, President and Chief Executive Officer, who brings decades of experience in specialty pharmaceuticals and drug delivery technologies. Chief Scientific Officer Christopher T. Getty oversees the company’s R&D efforts, directing preclinical modeling and formulation development. The executive team is supported by a board of directors with expertise spanning clinical development, regulatory affairs, and commercial strategy.
Nemus Bioscience’s strategic focus is on developing differentiated, patent-protected cannabinoid therapies with clear regulatory pathways. By targeting therapeutic areas with high unmet medical need and leveraging its unique delivery platform, the company aims to address conditions such as glaucoma, dermatologic disorders and gastrointestinal diseases. Nemus continues to advance its pipeline through rigorous clinical and nonclinical studies while exploring additional indications and partnerships to extend its market reach.
AI Generated. May Contain Errors.
